The abstract is read at the publisher; the summary is JClub's.
Higher baseline natural killer (NK) and myeloid gene signature expression is associated with improved clinical outcomes in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.
- Why it matters: Although tissue factor (TF) levels are required for drug binding, clinical responses in innovaTV 204 were independent of TF expression, leaving the immune basis of activity unclear.
- What they did: Pretreatment tumor samples from innovaTV 204 (phase II, single-arm; NCT03438396) were profiled for immune-related gene signatures, stratified by clinical response, and tested with in vitro ADCP/ADCC using tumor cell lines spanning variable TF expression.
- The result: NK- and myeloid-linked signatures were associated with better outcomes, and in vitro tisotumab vedotin induced myeloid-mediated ADCP and NK-mediated ADCC across TF expression levels, supporting immune effector involvement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.